{"id":1067957,"date":"2020-12-15T21:57:48","date_gmt":"2020-12-16T02:57:48","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/arecor-limited-first-patient-dosed-in-phase-i-clinical-trial-of-ultra-concentrated-rapid-acting-insulin-candidate-at278-for-diabetes\/"},"modified":"2024-08-18T11:41:22","modified_gmt":"2024-08-18T15:41:22","slug":"arecor-limited-first-patient-dosed-in-phase-i-clinical-trial-of-ultra-concentrated-rapid-acting-insulin-candidate-at278-for-diabetes","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/arecor-limited-first-patient-dosed-in-phase-i-clinical-trial-of-ultra-concentrated-rapid-acting-insulin-candidate-at278-for-diabetes.php","title":{"rendered":"Arecor Limited: First Patient Dosed in Phase I Clinical Trial of Ultra-Concentrated Rapid Acting Insulin Candidate, AT278, for Diabetes"},"content":{"rendered":"<p><![CDATA[Development of a rapid acting concentrated insulin for advanced delivery systems\u00a0and enabling fewer injections for high dose diabetics Development of a rapid acting concentrated insulin for advanced delivery systems\u00a0and enabling fewer injections for high dose diabetics]]><\/p>\n<p>View post:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"http:\/\/www.globenewswire.com\/news-release\/2020\/12\/15\/2145655\/0\/en\/Arecor-Limited-First-Patient-Dosed-in-Phase-I-Clinical-Trial-of-Ultra-Concentrated-Rapid-Acting-Insulin-Candidate-AT278-for-Diabetes.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Arecor Limited: First Patient Dosed in Phase I Clinical Trial of Ultra-Concentrated Rapid Acting Insulin Candidate, AT278, for Diabetes\">Arecor Limited: First Patient Dosed in Phase I Clinical Trial of Ultra-Concentrated Rapid Acting Insulin Candidate, AT278, for Diabetes<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>View post: Arecor Limited: First Patient Dosed in Phase I Clinical Trial of Ultra-Concentrated Rapid Acting Insulin Candidate, AT278, for Diabetes <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/arecor-limited-first-patient-dosed-in-phase-i-clinical-trial-of-ultra-concentrated-rapid-acting-insulin-candidate-at278-for-diabetes.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1067957","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1067957"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1067957"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1067957\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1067957"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1067957"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1067957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}